Neonatal Exendin-4 Reduces Growth, Fat Deposition and Glucose Tolerance during Treatment in the Intrauterine Growth-Restricted Lamb

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gatford, Kathryn L ^a   Sulaiman, Siti A ^a   Mohammad, Saidatul N B ^a   De Blasio, Miles J ^a   Harland, M Lyn ^a   Simmons, Rebecca A ^b   Owens, Julie A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; CELL FUNCTION; CELL STRUCTURE; CELLULAR SECRETION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE TOLERANCE; GROWTH INHIBITION; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; INTRAUTERINE GROWTH RETARDATION; LAMB; LIPID STORAGE; NEWBORN; NONHUMAN; PANCREAS ISLET BETA CELL; RISK ASSESSMENT; RISK FACTOR;

ADIPOSE TISSUE; ANIMALS; ANIMALS, NEWBORN; BODY COMPOSITION; BODY SIZE; CELL SIZE; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN-SECRETING CELLS; PEPTIDES; SHEEP; VENOMS;

EID: 84873704687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056553     Document Type: Article

References (85)

1. Newsome CA, Shiell AW, Fall CHD, Phillips DIW, Shier R, et al. (2003) Is birth weight related to later glucose and insulin metabolism?-a systematic review. Diab Med 20: 339-348.
2. Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, et al. (2008) Birth weight and risk of type 2 diabetes: A systematic review. JAMA 300: 2886-2897.
3. Kaijser M, Edstedt Bonamy A-K, Akre O, Cnattingius S, Granath F, et al. (2009) Perinatal risk factors for diabetes in later life. Diabetes 58: 523-526.
4. Eriksson M, Wallander MA, Krakau I, Wedel H, Svardsudd K, (2004) Birth weight and cardiovascular risk factors in a cohort followed until 80 years of age: the study of men born in 1913. J Internal Med 255: 236-246.
5. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, et al. (2002) Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 51: 1271-1280.
6. Veening MA, van Weissenbruch MM, Heine RJ, Delemarre-van de Waal HA, (2003) β-cell capacity and insulin sensitivity in prepubertal children born small for gestational age: Influence of body size during childhood. Diabetes 52: 1756-1760.
7. Mericq V, Ong KK, Bazaes R, Peña V, Avila A, et al. (2005) Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. Diabetologia 48: 2609-2614.
8. Robinson JS, Owens JA (1996) Pathophysiology of intrauterine growth failure. In: Gluckman PD, Heymann MA, editors. Pediatrics and Perinatology The Scientific Basis. 2 ed. London Arnold.pp. 290-297.
9. De Blasio MJ, Gatford KL, McMillen IC, Robinson JS, Owens JA, (2007) Placental restriction of fetal growth increases insulin action, growth, and adiposity in the young lamb. Endocrinology 148: 1350-1358.
10. De Blasio MJ, Gatford KL, Robinson JS, Owens JA, (2007) Placental restriction of fetal growth reduces size at birth and alters postnatal growth, feeding activity, and adiposity in the young lamb. Am J Physiol Regul Integr Comp Physiol 292: R875-886.
11. Owens JA, Thavaneswaran P, De Blasio MJ, McMillen IC, Robinson JS, et al. (2007) Sex-specific effects of placental restriction on components of the metabolic syndrome in young adult sheep. Am J Physiol Endocrinol Metab 292: E1879-1889.
12. Gatford KL, Mohammad SNB, Harland ML, De Blasio MJ, Fowden AL, et al. (2008) Impaired β-cell function and inadequate compensatory increases in β-cell mass after intrauterine growth restriction in sheep. Endocrinology 149: 5118-5127.
13. Simmons RA, Templeton LJ, Gertz SJ, (2001) Intrauterine growth retardation leads to the development of type 2 diabetes in the rat. Diabetes 50: 2279-2286.
14. Simmons RA, Suponitsky-Kroyter I, Selak MA, (2005) Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to β-cell failure. J Biol Chem 280: 28785-28791.
15. Stoffers DA, Desai BM, DeLeon DD, Simmons RA, (2003) Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52: 734-740.
16. Pinney S, Jaeckle Santos L, Han Y, Stoffers D, Simmons R, (2011) Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx-1 in the intrauterine growth retarded rat. Diabetologia 54: 2606-2614.
17. Brissova M, Blaha M, Spear C, Nicholson W, Radhika A, et al. (2005) Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis. Am J Physiol Endocrinol Metab 288: E707-714.
18. Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, et al. (2004) PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 114: E828-836.
19. Park JH, Stoffers DA, Nicholls RD, Simmons RA, (2008) Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 118: E2316-2324.
20. Reddy S, Elliott RB, (1988) Ontogenic development of peptide hormones in the mammalian fetal pancreas. Experientia 44: E1-9.
21. Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B, (2000) β-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 49: 1325-1333.
22. Piper K, Brickwood S, Turnpenny LW, Cameron IT, Ball SG, et al. (2004) Beta cell differentiation during early human pancreas development. J Endocrinol 181: 11-23.
23. Limesand SW, Jensen J, Hutton JC, Hay WW Jr, (2005) Diminished β-cell replication contributes to reduced β-cell mass in fetal sheep with intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol 288: R1297-1305.
24. Otonkoski T, Andersson S, Knip M, O S, (1988) Maturation of insulin response to glucose during human fetal and neonatal development. Studies with perifusion of pancreatic isletlike cell clusters. Diabetes 37: 286-291.
25. Bassett JM, (1977) Glucagon, insulin and glucose homeostasis in the fetal lamb. Ann Rech Vet 8: 362-373.
26. Fowden AL, (1980) Effects of arginine and glucose on the release of insulin in the sheep fetus. J Endocrinol 87: E293-301.
27. Rozance PJ, Limesand SW, Hay WW, (2006) Decreased nutrient-stimulated insulin secretion in chronically hypoglycemic late-gestation fetal sheep is due to an intrinsic islet defect. Am J Physiol Endocrinol Metab 291: E404-E411.
28. Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S, (1997) Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 138: 1736-1741.
29. Petrik J, Arany E, McDonald TJ, Hill DJ, (1998) Apoptosis in the pancreatic islet cells of the neonatal rat is associated with a reduced expression of insulin-like growth factor II that may act as a survival factor. Endocrinology 139: 2994-3004.
30. Petrik J, Reusens B, Arany E, Remacle C, Coelho C, et al. (1999) A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic expression of insulin-like growth factor-II. Endocrinology 140: 4861-4873.
31. Navarro-Tableros V, Fiordelisio T, Hernández-Cruz A, Hiriart M, (2007) Physiological development of insulin secretion, calcium channels, and GLUT2 expression of pancreatic rat β-cells. Am J Physiol Endocrinol Metab 292: E1018-E1029.
32. Tan C, Tuch BE, Tu J, Brown SA, (2002) Role of NADH shuttles in glucose-induced insulin secretion from fetal β-cells. Diabetes 51: 2989-2996.
33. National Health and Medical Research Council of Australia (2004) Australian code of practice for the care and use of animals for scientific purposes, 7th edition. Canberra: Australian Government Publishing Service. 82 p.
34. Thompson GE, (1983) The intake of milk by suckled, newborn lambs and the effects of twinning and cold exposure. British J Nutr 50: 151-156.
35. Gatford KL, De Blasio MJ, Thavaneswaran P, Robinson JS, McMillen IC, et al. (2004) Postnatal ontogeny of glucose homeostasis and insulin action in sheep. Am J Physiol Endocrinol Metab 286: E1050-1059.
36. Limesand SW, Rozance PJ, Zerbe GO, Hutton JC, Hay WW Jr, (2006) Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. Endocrinology 147: 1488-1497.
37. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, et al. (2008) Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57: 2577-2587.
38. Cabou C, Vachoux C, Campistron G, Drucker DJ, Burcelin R, (2011) Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ. Diabetes 60: 2245-2256.
39. Imeryüz N, Yeǧen BÇ, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, et al. (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. American Journal of Physiology- Gastrointestinal and Liver Physiology 273: G920-G927.
40. De Blasio MJ, Gatford KL, McMillen IC, Robinson JS, Owens JA, (2007) Placental restriction of fetal growth increases insulin action, growth and adiposity in the young lamb. Endocrinology 148: 1350-1358.
41. Ong KKL, Ahmed ML, Emmett PM, Preece MA, Dunger DB, (2000) Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. British Medical Journal 320: 967-971.
42. Duffield JA, Vuocolo T, Tellam R, Yuen BS, Muhlhausler BS, et al. (2008) Placental restriction of fetal growth decreases IGF1 and leptin mRNA expression in the perirenal adipose tissue of late gestation fetal sheep. American Journal of Physiology 294: R1413-R1419.
43. Duffield JA, Vuocolo T, Tellam R, McFarlane JR, Kauter KG, et al. (2009) Intrauterine growth restriction and the sex specific programming of leptin and peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA expression in visceral fat in the lamb. Pediatric Research 66: 59-65.
44. Newsome CA, Shiell AW, Fall CHD, Phillips DIW, Shier R, et al. (2003) Is birth weight related to later glucose and insulin metabolism?- a systemic review. Diabetic Medicine 20: 339-348.
45. Mericq V, Ong KK, Bazaes R, Pena V, Avila A, et al. (2005) Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. Diabetologia 48: 2609-2614.
46. Muhlhausler BS, Duffield JA, Ozanne SE, Pilgrim C, Turner N, et al. (2009) The transition from fetal growth restriction to accelerated postnatal growth: a potential role for insulin signalling in skeletal muscle. The Journal of Physiology 587: 4199-4211.
47. De Blasio MJ, Gatford KL, Harland ML, Robinson JS, Owens JA, (2012) Placental restriction reduces insulin sensitivity and expression of insulin signaling and glucose transporter genes in skeletal muscle, but not liver, in young sheep. Endocrinology 153: 2142-2151.
48. Owens JA, Harland ML, De Blasio MJ, Gatford KL, Robinson JS, (2007) Restriction of placental and fetal growth reduces expression of insulin signalling and glucose transporter genes in skeletal muscle of young lambs. Early Human Development 83: S134 (abstract).
49. Stoffers DA, Desai BM, De Leon DD, Simmons RA, (2003) Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52: 734-740.
50. Doyle ME, Egan JM, (2001) Glucagon-like peptide-1. Recent Prog Horm Res 56: 377-400.
51. Garber AJ, (2011) Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care pp. S258+.
52. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, et al. (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obesity Metab 8: 436-447.
53. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, et al. (2004) Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635.
54. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-1100.
55. Wang QW, Brubaker PLB, (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273.
56. Ding X, Saxena NK, Lin S, Gupta N, Anania FA, (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181.
57. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, et al. (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089.
58. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, et al. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307.
59. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, et al. (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90: 5991-5997.
60. Kwon DY, Kim YS, Ahn IS, Kim DS, Kang S, et al. (2009) Exendin-4 potentiates insulinotropic action partly via increasing β-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci 111: 361-371.
61. Jahr H, Ratzmann KP, Beckert R, Besch W, Hahn HJ, (1983) Enhanced synthesis, storage, and secretion of insulin in pancreatic islets derived from obese subjects. Metabolism 32: 1101-1106.
62. Hansen BC, Bodkin NL, (1990) Beta-cell hyperresponsiveness: earliest event in development of diabetes in monkeys. Am J Physiol Regul Integr Comp Physiol 259: R612-R617.
63. Jetton TL, Lausier J, LaRock K, Trotman WE, Larmie B, et al. (2005) Mechanisms of compensatory β-cell growth in insulin-resistant rats. Diabetes 54: 2294-2304.
64. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, et al. (2012) Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study. Obesity 20: 364-370.
65. Zander M, Madsbad S, Madsen JL, Holst JJ, (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.
66. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, et al. (2005) Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076.
67. Li L, Yang G, Li Q, Tan X, Liu H, et al. (2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obesity Metab 10: 921-930.
68. Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, et al. (2009) Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem Biophys Res Comm 390: 809-814.
69. Edwards CMB, Stanley SA, Davis R, Brynes AE, Frost GS, et al. (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281: E155-161.
70. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, et al. (2008) Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24: 2943-2952.
71. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, et al. (2008) Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regulatory Peptides DOI:10.1016/j.regpep.2008.07.003.
72. Sano H, Takebayashi A, Kodama Y, Nakamura K, Ito H, et al. (1999) Effects of feed restriction and cold exposure on glucose metabolism in response to feeding and insulin in sheep. J Anim Sci 77: 2564-2573.
73. Katsumata M, Burton KA, Li J, Dauncey MJ, (1999) Suboptimal energy balance selectively up-regulates muscle GLUT gene expression but reduces insulin-dependent glucose uptake during postnatal development. FASEB J 13: 1405-1413.
74. Kastin AJ, Akerstrom V, (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obesity Rel Metab Disorders 27: 313.
75. Kwon DY, Kim YS, Ahn IS, Kim DS, Kang S, et al. (2009) Exendin-4 potentiates insulinotropic action partly via increasing β-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. Journal of Pharmacological Sciences 111: 361-371.
76. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, et al. (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 90: 5991-5997.
77. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, et al. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034.
78. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, et al. (2005) Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076.
79. Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, et al. (2011) Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. Journal of Clinical Endocrinology & Metabolism 96: 1763-1770.
80. Belfiore F, Iannello S, (1998) Insulin resistance in obesity: Metabolic mechanisms and measurement methods. Mol Genetics Metab 65: 121-128.
81. Summermatter S, Marcelino H, Arsenijevic D, Buchala A, Aprikian O, et al. (2009) Adipose tissue plasticity during catch-up fat driven by thrifty metabolism. Diabetes 58: 2228-2237.
82. Forsén T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, et al. (2000) The fetal and childhood growth of persons who develop type 2 diabetes. Ann Internal Med 133: 176-182.
83. Ong KKL, Ahmed ML, Emmett PM, Preece MA, Dunger DB, (2000) Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ 320: 967-971.
84. De Blasio MJ, Gatford KL, Robinson JS, Owens JA, (2006) Placental restriction alters circulating thyroid hormone in the young lamb postnatally. American Journal of Physiology 291: R1016-R1024.
85. De Blasio MJ, Gatford KL, Robinson JS, Owens JA, (2007) Placental restriction of fetal growth reduces size at birth and alters postnatal growth, feeding activity and adiposity in the young lamb. American Journal of Physiology 292: R875-R886.